The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Renal Replacement Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Renal Replacement Therapy


Psychiatry related information on Renal Replacement Therapy


High impact information on Renal Replacement Therapy


Chemical compound and disease context of Renal Replacement Therapy


Biological context of Renal Replacement Therapy


Anatomical context of Renal Replacement Therapy


Associations of Renal Replacement Therapy with chemical compounds


Gene context of Renal Replacement Therapy


Analytical, diagnostic and therapeutic context of Renal Replacement Therapy


  1. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. Remuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B.D., de Zeeuw, D., Hille, D.A., Shahinfar, S., Carides, G.W., Brenner, B.M. J. Am. Soc. Nephrol. (2004) [Pubmed]
  2. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane. van der Pijl, J.W., Daha, M.R., van den Born, J., Verhagen, N.A., Lemkes, H.H., Bucala, R., Berden, J.H., Zwinderman, A.H., Bruijn, J.A., van Es, L.A., van der Woude, F.J. Diabetologia (1998) [Pubmed]
  3. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. Hadjadj, S., Belloum, R., Bouhanick, B., Gallois, Y., Guilloteau, G., Chatellier, G., Alhenc-Gelas, F., Marre, M. J. Am. Soc. Nephrol. (2001) [Pubmed]
  4. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Foley, R.N., Murray, A.M., Li, S., Herzog, C.A., McBean, A.M., Eggers, P.W., Collins, A.J. J. Am. Soc. Nephrol. (2005) [Pubmed]
  5. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Fish, D.N., Teitelbaum, I., Abraham, E. Antimicrob. Agents Chemother. (2005) [Pubmed]
  6. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Holdaas, H., Fellström, B., Jardine, A.G., Nyberg, G., Grönhagen-Riska, C., Madsen, S., Neumayer, H.H., Cole, E., Maes, B., Ambühl, P., Logan, J.O., Staffler, B., Gimpelewicz, C. Nephrol. Dial. Transplant. (2005) [Pubmed]
  7. Cost and price in the NHS: the importance of monetary value in the decision-making framework--the case of purchasing renal replacement therapy. Moore, R., Marriott, N. Health services management research : an official journal of the Association of University Programs in Health Administration / HSMC, AUPHA. (1999) [Pubmed]
  8. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Schortgen, F., Lacherade, J.C., Bruneel, F., Cattaneo, I., Hemery, F., Lemaire, F., Brochard, L. Lancet (2001) [Pubmed]
  9. Treatment of end-stage renal failure due to diabetes in the United Kingdom, 1975-84. Cameron, J.S., Challah, S. Lancet (1986) [Pubmed]
  10. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Facchini, F.S., Saylor, K.L. Diabetes (2003) [Pubmed]
  11. Can renal replacement be deferred by a supplemented very low protein diet? Walser, M., Hill, S. J. Am. Soc. Nephrol. (1999) [Pubmed]
  12. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Malone, R.S., Fish, D.N., Abraham, E., Teitelbaum, I. Antimicrob. Agents Chemother. (2001) [Pubmed]
  13. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Szczech, L.A., Gupta, S.K., Habash, R., Guasch, A., Kalayjian, R., Appel, R., Fields, T.A., Svetkey, L.P., Flanagan, K.H., Klotman, P.E., Winston, J.A. Kidney Int. (2004) [Pubmed]
  14. A prospective laboratory-based audit of gentamicin use and therapeutic monitoring. Saunders, N.J., Adams, D.J., Lynn, W.A. J. Antimicrob. Chemother. (1995) [Pubmed]
  15. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Sharp, C.K., Zeligman, B.E., Johnson, A.M., Duley, I., Gabow, P.A. Am. J. Kidney Dis. (1999) [Pubmed]
  16. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Vargas Hein, O., von Heymann, C., Lipps, M., Ziemer, S., Ronco, C., Neumayer, H.H., Morgera, S., Welte, M., Kox, W.J., Spies, C. Intensive care medicine. (2001) [Pubmed]
  17. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International (DERI) U.S.-Japan Mortality Study Group. Matsushima, M., Tajima, N., LaPorte, R.E., Orchard, T.J., Tull, E.S., Gower, I.F., Kitagawa, T. Diabetologia (1995) [Pubmed]
  18. Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. Maruyama, Y., Nordfors, L., Stenvinkel, P., Heimburger, O., Bárány, P., Pecoits-Filho, R., Axelsson, J., Hoff, C.M., Holmes, C.J., Schalling, M., Lindholm, B. Blood Purif. (2005) [Pubmed]
  19. Prognosis in critically ill children requiring continuous renal replacement therapy. Fernández, C., López-Herce, J., Flores, J.C., Galaviz, D., Rupérez, M., Brandstrup, K.B., Bustinza, A. Pediatr. Nephrol. (2005) [Pubmed]
  20. Serum bile acids and pruritus in hemodialysis patients. Mamianetti, A., Tripodi, V., Vescina, C., Garrido, D., Vizioli, N., Carducci, C., Agost Carreño, C. Clin. Nephrol. (2000) [Pubmed]
  21. Bone resorption and "relative" immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation. Wang, P.L., Meyer, M.M., Orloff, S.L., Anderson, S. Am. J. Kidney Dis. (2004) [Pubmed]
  22. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla, A., Gascón, A.R., Maynar, J., Arzuaga, A., Toral, D., Pedraz, J.L. Clinical therapeutics. (2005) [Pubmed]
  23. Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure. Alkhunaizi, A.M., Chan, L. J. Am. Soc. Nephrol. (1996) [Pubmed]
  24. Survival during renal replacement therapy for diabetic end-stage renal disease in Pima Indians. Nelson, R.G., Hanson, R.L., Pettitt, D.J., Knowler, W.C., Bennett, P.H. Diabetes Care (1996) [Pubmed]
  25. The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Dishy, V., Cohen Pour, M., Feldman, L., Naftali, T., Baumer, M., Efrati, S., Golik, A., Horne, T., Weissgarten, J. Clin. Pharmacol. Ther. (2004) [Pubmed]
  26. Simplified citrate anticoagulation for continuous renal replacement therapy. Tolwani, A.J., Campbell, R.C., Schenk, M.B., Allon, M., Warnock, D.G. Kidney Int. (2001) [Pubmed]
  27. Recent insights into the molecular genetics of the homocysteine metabolism. Födinger, M., Wagner, O.F., Hörl, W.H., Sunder-Plassmann, G. Kidney Int. Suppl. (2001) [Pubmed]
  28. Type-IV collagen related diseases. Pescucci, C., Longo, I., Bruttini, M., Mari, F., Renieri, A. J. Nephrol. (2003) [Pubmed]
  29. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Borazan, A., Ustün, H., Ustundag, Y., Aydemir, S., Bayraktaroglu, T., Sert, M., Yilmaz, A. Mediators of inflammation. (2004) [Pubmed]
  30. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Michaud, J., Dubé, P., Naud, J., Leblond, F.A., Desbiens, K., Bonnardeaux, A., Pichette, V. Br. J. Pharmacol. (2005) [Pubmed]
  31. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Yao, Q., Nordfors, L., Axelsson, J., Heimbürger, O., Qureshi, A.R., Báràny, P., Lindholm, B., Lönnqvist, F., Schalling, M., Stenvinkel, P. Atherosclerosis (2005) [Pubmed]
  32. Anti-interleukin-1 alpha autoantibodies in hemodialysis patients. Sunder-Plassmann, G., Sedlacek, P.L., Sunder-Plassmann, R., Derfler, K., Swoboda, K., Fabrizii, V., Hirschl, M.M., Balcke, P. Kidney Int. (1991) [Pubmed]
  33. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Singh, N., Paterson, D.L., Gayowski, T., Wagener, M.M., Marino, I.R. Transplantation (2001) [Pubmed]
  34. Glomerular spherical electron dense deposits in a patient undergoing long-term regional heparinization. Yamase, H.T., Gillies, C., Kaplan, A.A. Am. J. Kidney Dis. (1988) [Pubmed]
  35. Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro. Ittner, K.P., Roth, G., Gruber, M., Pawlik, M., Taeger, K. J. Antimicrob. Chemother. (2005) [Pubmed]
  36. Can the nephrologist prevent dialysis-related amyloidosis? Zingraff, J., Drüeke, T. Am. J. Kidney Dis. (1991) [Pubmed]
WikiGenes - Universities